List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5056854/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	What information can we gain from performing adaptive radiotherapy of head and neck cancer patients from the past 10 years?. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 502-516.	0.6	6
2	Development of a quasiâ€humanoid phantom to perform dosimetric and radiobiological measurements for outâ€ofâ€field doses from external beam radiation therapy. Journal of Applied Clinical Medical Physics, 2022, 23, e13514.	0.8	4
3	3D printing of individual skin brachytherapy applicator: design, manufacturing, and early clinical results. Journal of Contemporary Brachytherapy, 2022, 14, 205-214.	0.4	4
4	Radiation Oncology in a Humanitarian Emergency: Experience with Ukrainian Refugees at Two Cancer Centers in Poland and Italy. Advances in Radiation Oncology, 2022, , 100956.	0.6	3
5	Thermal Boost to Breast Tumor Bed—New Technique Description, Treatment Application and Example Clinical Results. Life, 2022, 12, 512.	1.1	1
6	Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer. Life, 2022, 12, 394.	1,1	1
7	Influence of Specific Treatment Parameters on Nontarget and Out-of-Field Doses in a Phantom Model of Prostate SBRT with CyberKnife and TrueBeam. Life, 2022, 12, 628.	1.1	2
8	Criteria for Verification and Replanning Based on the Adaptive Radiotherapy Protocol "Best for Adaptive Radiotherapy―in Head and Neck Cancer. Life, 2022, 12, 722.	1,1	2
9	Evaluation and risk factors of volume and dose differences of selected structures in patients with head and neck cancer treated on Helical TomoTherapy by using Deformable Image Registration tool. Polish Journal of Medical Physics and Engineering, 2022, 28, 60-68.	0.2	2
10	Cellular Damage in the Target and Out-Of-Field Peripheral Organs during VMAT SBRT Prostate Radiotherapy: An In Vitro Phantom-Based Study. Cancers, 2022, 14, 2712.	1.7	3
11	Nontarget and Out-of-Field Doses from Electron Beam Radiotherapy. Life, 2022, 12, 858.	1.1	3
12	Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Biomedicines, 2022, 10, 1600.	1.4	3
13	Dosimetric assessment of the impact of low-cost materials used in stereolithography in high-dose-rate brachytherapy. Journal of Contemporary Brachytherapy, 2021, 13, 188-194.	0.4	8
14	Deep inspiration breath hold reduces the mean heart dose in left breast cancer radiotherapy. Radiology and Oncology, 2021, 55, 212-220.	0.6	14
15	Future Perspectives of Proton Therapy in Minimizing the Toxicity of Breast Cancer Radiotherapy. Journal of Personalized Medicine, 2021, 11, 410.	1.1	11
16	Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres. Scientific Reports, 2021, 11, 12323.	1.6	1
17	Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages. Scientific Reports, 2021, 11, 13942.	1.6	2
18	PO-1782 Doses from 2.5 MV and 6 MV 2D-imaging in IGRT, measured with MOSFET detectors. Radiotherapy and Oncology, 2021, 161, S1508-S1509.	0.3	0

#	Article	IF	CITATIONS
19	PO-1785 Non-target dose reduction at phantom study for prostate radiotherapy using TrueBeam and CyberKnife. Radiotherapy and Oncology, 2021, 161, S1511-S1512.	0.3	0
20	The impact of different optimization strategies on the agreement between planned and delivered doses during volumetric modulated arc therapy for total marrow irradiation. Wspolczesna Onkologia, 2021, 25, 100-106.	0.7	0
21	3D-printed surface applicators for brachytherapy: a phantom study. Journal of Contemporary Brachytherapy, 2021, 13, 549-562.	0.4	6
22	Comparison of Dose–Response Curves between EBT-XD and EBT3 Radiochromic Films at High Dose Range (2000–4500 cGy) for a 175 MeV Proton Beam. Physics of Particles and Nuclei Letters, 2021, 18, 691-699.	0.1	1
23	Assessment of biological parameters in head and neck cancer based on in vivo distribution of ¹⁸ F-FDG-FLT-FMISO-PET/CT images. Tumori, 2020, 106, 33-38.	0.6	7
24	How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement. Lancet Oncology, The, 2020, 21, e42-e54.	5.1	45
25	Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment. British Journal of Radiology, 2020, 93, 20180781.	1.0	7
26	Impact of COVID-19 on the performance of a radiation oncology department at a major comprehensive cancer centre in Poland during the first ten weeks of the epidemic. Reports of Practical Oncology and Radiotherapy, 2020, 25, 820-827.	0.3	12
27	Impact of different optimization strategies on the compatibility between planned and delivered doses during radiation therapy of cervical cancer. Reports of Practical Oncology and Radiotherapy, 2020, 25, 412-421.	0.3	7
28	Cancer incidence in the Greater Poland region as compared to Europe. Reports of Practical Oncology and Radiotherapy, 2020, 25, 632-636.	0.3	6
29	Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project. Radiation Oncology, 2020, 15, 208.	1.2	1
30	Ultra-hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, S62-S63.	0.4	5
31	Evaluation of three VMAT-TMI planning methods to find an appropriate balance between plan complexity and the resulting dose distribution. Physica Medica, 2020, 75, 26-32.	0.4	4
32	Evolution of treatment planning and dose delivery methods during radiotherapy for patients undergoing bone marrow transplantation: a review. Nukleonika, 2020, 65, 19-30.	0.3	2
33	PO-1361: Treatment plan preparation and verification for total body irradiation using tomotherapy. Radiotherapy and Oncology, 2020, 152, S722.	0.3	0
34	PO-1433: Out-of-Field doses in radiotherapy for prostate cancer with CyberKnife – phantom measurement. Radiotherapy and Oncology, 2020, 152, S761-S762.	0.3	0
35	PO-1946: Risk management for intraoperative electron radiotherapy accelerators. Radiotherapy and Oncology, 2020, 152, S1082-S1083.	0.3	0
36	PO-1174: Results of a multinational clinical audit for prostate cancer radiotherapy: the IROCA project. Radiotherapy and Oncology, 2020, 152, S618.	0.3	0

#	Article	IF	CITATIONS
37	Adapting training for medical physicists to match future trends in radiation oncology. Physics and Imaging in Radiation Oncology, 2019, 11, 71-75.	1.2	6
38	Relations between dose cumulated in organs at risk and treatment based on different image-guidance strategies of cervical cancer. Physica Medica, 2019, 57, 183-190.	0.4	9
39	Calculation and measurement of doses in the surface layers of a phantom when using Tomotherapy. Reports of Practical Oncology and Radiotherapy, 2019, 24, 251-262.	0.3	2
40	miRNAs Set Expression Profiles in Whole Blood During Prostate Cancer Patients Treatment. Biomarkers Journal, 2018, 04, .	0.2	1
41	In Regard to Burmeister etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1592.	0.4	1
42	New developments and controversies in cervical cancer. Reports of Practical Oncology and Radiotherapy, 2018, 23, 481-483.	0.3	2
43	Patient safety in external beam radiotherapy, results of the ACCIRAD project: Recommendations for radiotherapy institutions and national authorities on assessing risks and analysing adverse error-events and near misses. Radiotherapy and Oncology, 2018, 127, 164-170.	0.3	11
44	Dose distribution at the Bragg peak: Dose measurements using EBT and RTQA gafchromic film set at two positions to the central beam axis. Medical Physics, 2017, 44, 1538-1544.	1.6	2
45	Relations between doses cumulated in bone marrow and dose delivery techniques during radiation therapy of cervical and endometrial cancer. Physica Medica, 2017, 36, 54-59.	0.4	12
46	Low dose out-of-field radiotherapy, part 1: Measurement of scattered doses. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 345-351.	0.6	12
47	Low dose out-of-field radiotherapy, part 3: Qualitative and quantitative impact of scattered out-of-field radiation on MDA-MB-231 cell lines. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 358-364.	0.6	6
48	Low dose out-of-field radiotherapy, part 2: Calculating the mean photon energy values for the out-of-field photon energy spectrum from scattered radiation using Monte Carlo methods. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 352-357.	0.6	11
49	Patient safety in external beam radiotherapy, results of the ACCIRAD project: Current status of proactive risk assessment, reactive analysis of events, and reporting and learning systems in Europe. Radiotherapy and Oncology, 2017, 123, 29-36.	0.3	15
50	Improving radiation oncology through clinical audits: Introducing the IROCA project. Reports of Practical Oncology and Radiotherapy, 2017, 22, 408-414.	0.3	9
51	Carcinogenesis induced by low-dose radiation. Radiology and Oncology, 2017, 51, 369-377.	0.6	35
52	Measurements of doses from photon beam irradiation and scattered neutrons in an anthropomorphic phantom model of prostate cancer: a comparison between 3DCRT, IMRT and tomotherapy. Nukleonika, 2017, 62, 29-35.	0.3	6
53	Dosimetric verification of dose calculation algorithm in the lung during total marrow irradiation using helical tomotherapy. Journal of Cancer Research and Therapeutics, 2017, 13, 33.	0.3	2
54	Dosimetric study of the protection level of the bone marrow in patients with cervical or endometrial cancer for three radiotherapy techniques - 3D CRT, IMRT and VMAT. Study protocol Polish Journal of Medical Physics and Engineering, 2016, 22, 11-15.	0.2	0

#	Article	IF	CITATIONS
55	Impact of the Intra- and Inter-observer Variability in the Delineation of Parotid Glands on the Dose Calculation During Head and Neck Helical Tomotherapy. Technology in Cancer Research and Treatment, 2015, 14, tcrtexpress.201.	0.8	3
56	Opieka onkologiczna w Wielkopolsce na tle zmian systemu ochrony zdrowia w Polsce – cz. 1. Kompleksowość Å›wiadczeÅ,,, koszty systemowe i finasowanie. Zeszyty Naukowe WCO Letters in Oncology Science, 2015, 12, 63-71.	0.2	1
57	The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiotherapy and Oncology, 2015, 116, 45-50.	0.3	94
58	Impact of the Intra- and Inter-observer Variability in the Delineation of Parotid Glands on the Dose Calculation During Head and Neck Helical Tomotherapy. Technology in Cancer Research and Treatment, 2015, 14, 467-474.	0.8	4
59	Application of failure mode and effects analysis to intracranial stereotactic radiation surgery by linear accelerator In Regard to Masini et al. Practical Radiation Oncology, 2015, 5, e53-e54.	1.1	2
60	Medical physics in radiotherapy: The importance of preserving clinical responsibilities and expanding the profession's role in research, education, and quality control. Reports of Practical Oncology and Radiotherapy, 2015, 20, 161-169.	0.3	20
61	Annual Board of Editors meeting in Prague: Current and future directions for RPOR. Reports of Practical Oncology and Radiotherapy, 2015, 20, viii-ix.	0.3	0
62	The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiotherapy and Oncology, 2015, 116, 38-44.	0.3	131
63	National Programme for Prevention and Early Detection of Head and Neck Cancer. Otolaryngologia Polska, 2015, 69, 31-40.	0.2	3
64	Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiology and Oncology, 2014, 48, 1-10.	0.6	122
65	Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 155-164.	0.3	140
66	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 165-177.	0.3	61
67	Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 178-186.	0.3	85
68	Beam orientation in stereotactic radiosurgery using an artificial neural network. Radiotherapy and Oncology, 2014, 111, 296-300.	0.3	10
69	Wax boluses and accuracy of EBT and RTQA radiochromic film detectors in radiotherapy with the JINR Phasotron proton beam. Reports of Practical Oncology and Radiotherapy, 2014, 19, 12-18.	0.3	4
70	In regard to: Letter to the Editor "The impact of early life exposure to diagnostic and therapeutic radiation on childhood cancer risk― Phys Med 2013 29, 221–223. Physica Medica, 2014, 30, 1.	0.4	3
71	Patient safety in external beam radiotherapy – Guidelines on risk assessment and analysis of adverse error-events and near misses: Introducing the ACCIRAD project. Radiotherapy and Oncology, 2014, 112, 194-198.	0.3	15
72	Cancer incidence and mortality in the Greater Poland Region—Analysis of the year 2010 and future trends. Reports of Practical Oncology and Radiotherapy, 2014, 19, 296-300.	0.3	26

#	Article	IF	CITATIONS
73	Challenges in organizing effective oncology service: inter-European variability in the example of head and neck cancers. European Archives of Oto-Rhino-Laryngology, 2014, 271, 2343-2347.	0.8	4
74	Dosimetric consequences of prostate-based couch shifts on the precision of dose delivery during simultaneous IMRT irradiation of the prostate, seminal vesicles and pelvic lymph nodes. Physica Medica, 2014, 30, 228-233.	0.4	18
75	Preoperative radiotherapy for rectal cancer: a comparative study of quality control adherence at two cancer hospitals in Spain and Poland. Radiology and Oncology, 2014, 48, 210-218.	0.6	7
76	Status zawodu fizyka medycznego w Polsce i weryfikacja uprawnień zagranicznych. Zeszyty Naukowe WCO Letters in Oncology Science, 2013, 10, 72-76.	0.2	1
77	Radiotherapy capacity in Europe. Lancet Oncology, The, 2013, 14, e196-e198.	5.1	10
78	Radiotherapy facilities, equipment, and staffing in Poland: 2005–2011. Reports of Practical Oncology and Radiotherapy, 2013, 18, 159-172.	0.3	17
79	In Regard to Albert and Das. International Journal of Radiation Oncology Biology Physics, 2013, 87, 432.	0.4	5
80	Evaluation of clinical benefits achievable by using different optimization algorithms during real-time prostate brachytherapy. Physica Medica, 2013, 29, 111-116.	0.4	8
81	SU-C-137-06: What Was the Impact Of European Medical Exposure Directive On Regulation On Clinical Practice Associated with Accidental Exposures, Reporting and Risk Analyses in Radiotherapy?. Medical Physics, 2013, 40, 85-86.	1.6	0
82	Doses in organs at risk during head and neck radiotherapy using IMRT and 3D-CRT. Radiology and Oncology, 2012, 46, 328-36.	0.6	17
83	The importance of accurate treatment planning, delivery, and dose verification. Reports of Practical Oncology and Radiotherapy, 2012, 17, 63-65.	0.3	101
84	Physics and technology in ESTRO and in Radiotherapy and Oncology: Past, present and into the 4th dimension. Radiotherapy and Oncology, 2011, 100, 327-332.	0.3	49
85	Values of biologically equivalent doses in healthy tissues: Comparison of PDR and HDR brachytherapy techniques. Brachytherapy, 2010, 9, 165-170.	0.2	7
86	Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Therapy, 2010, 17, 465-475.	2.2	16
87	Biology Contributions Influence of length of interval between pulses in PDR brachytherapy (PDRBT) on value of Biologically Equivalent Dose (BED) in healthy tissues. Journal of Contemporary Brachytherapy, 2010, 2, 64-70.	0.4	0
88	Dosimetric verification of dose optimisation algorithm during endovascular brachytherapy of the peripheral vessels. Reports of Practical Oncology and Radiotherapy, 2009, 14, 114-121.	0.3	2
89	The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical Tomotherapy. Reports of Practical Oncology and Radiotherapy, 2009, 14, 133-145.	0.3	13
90	The comparison of doses measured by radiochromic films and semiconductor detector in a 175MeV proton beam. Physica Medica, 2009, 25, 105-110.	0.4	11

#	Article	IF	CITATIONS
91	Cost-effectiveness of the modifications in the quality assurance system in radiotherapy in the example of in-vivo dosimetry. Physica Medica, 2009, 25, 201-206.	0.4	11
92	TRAINING OF MEDICAL PHYSICISTS AND FORMAL REQUIREMENTS OF RADIOTHERAPY DEPARTMENTS RELATED TO EXPERTISE IN MEDICAL PHYSICS. Radiotherapy and Oncology, 2009, 92, S156.	0.3	2
93	The influence of legislative changes on quality and costs in radiotherapy. Reports of Practical Oncology and Radiotherapy, 2008, 13, 280-286.	0.3	2
94	Application of the NaÃ ⁻ ve Bayesian Classifier to optimize treatment decisions. Radiotherapy and Oncology, 2008, 86, 211-216.	0.3	65
95	Patterns of care for brachytherapy in Europe (PC BE) in Spain and Poland: Comparative results. Reports of Practical Oncology and Radiotherapy, 2007, 12, 39-45.	0.3	8
96	The rotary dual technique for total skin irradiation in the treatment of mycosis fungoides – a description of the applied method. Reports of Practical Oncology and Radiotherapy, 2006, 11, 29-37.	0.3	22
97	A career pathway for radiation therapists. Does it really exist?: In regard to Kresl et al. (Int J Radiat) Tj ETQq1 1 0.7 292.	84314 rg 0.4	BT /Overlock 1
98	How the implementation of an in-vivo dosimetry protocol improved the dose delivery accuracy in head and neck radiotherapy. Neoplasma, 2004, 51, 155-8.	0.7	8
99	Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer. Reports of Practical Oncology and Radiotherapy, 2003, 8, 49-56.	0.3	3
100	Poznań Cancer Centre 1953–2003. Reports of Practical Oncology and Radiotherapy, 2003, 8, 85-95.	0.3	6
101	Thermoluminescent dosimetry in rotary-dual technique of the total skin electron irradiation. Neoplasma, 2003, 50, 125-30.	0.7	11
102	Allogeneic bone marrow transplantation in children with acute lymphoblastic leukaemia in the first and second complete remission conditioned with fractionated total body irradiation and cyclophosphamide or etoposide. Reports of Practical Oncology and Radiotherapy, 2002, 7, 117-125.	0.3	1
103	Evaluation of an electronic portal imaging device (target view, ge) as a quality assurance tool. Reports of Practical Oncology and Radiotherapy, 2001, 6, 169-172.	0.3	7
104	Total body irradiation before bone marrow transplantation: aims and results. Advances in Experimental Medicine and Biology, 2001, 495, 277-282.	0.8	5
105	Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Advances in Experimental Medicine and Biology, 2001, 495, 411-418.	0.8	5
106	Cobalt 60 versus 15 MeV photons during total body irradiation: doses in the critical organs and complexicity of the procedure. Annals of Transplantation, 2001, 6, 18-22.	0.5	5
107	Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunology Letters, 2000, 74, 81-86.	1.1	27
108	The accuracy of dose determination during total body irradiation. Strahlentherapie Und Onkologie, 1999, 175, 208-212.	1.0	15

#	Article	IF	CITATIONS
109	Immunogene Therapy of Human Melanoma. Advances in Experimental Medicine and Biology, 1998, 451, 557-560.	0.8	5
110	Beam filter and compensators during total body irradiation on Cobalt-60. Reports of Practical Oncology, 1997, 2, 77-81.	0.0	1
111	Gene Therapy of Human Melanoma â \in " from Animal Experiments to the Clinical Trial. , 1997, , 27-39.		0
112	The influence of the gap in postoperative radiotherapy patients with carcinoma of the larynx. Reports of Practical Oncology, 1996, 1, 49-51.	0.0	0
113	Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine. Reports of Practical Oncology, 1996, 1, 104-109.	0.0	Ο
114	Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, PoznaÅ,,, Poland. Human Gene Therapy, 1995, 6, 805-811.	1.4	34
115	Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia. Acta Haematologica Polonica, 1995, 26, 377-84.	0.1	7
116	The accuracy of dose in vivo measurements during total body irradiation. , 0, , .		0

116 The accuracy of dose in vivo measurements during total body irradiation. , 0, , .

8